Latest & greatest articles for phentermine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on phentermine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on phentermine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for phentermine

1. Phentermine

Phentermine Top results for phentermine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for phentermine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release

Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release To assess the ability of medication-assisted weight loss to prevent diabetes as a function of the baseline weighted Cardiometabolic Disease Staging (CMDS) score.We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL-assessing (...) efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. In these double-blind phase III trials, overweight/obese adult patients were treated with a lifestyle intervention and randomly assigned to placebo versus once-daily oral phentermine/topiramate ER. The weighted CMDS score was calculated using baseline quantitative clinical data including waist circumference, blood glucose, blood pressure, and blood lipids. Incident diabetes was defined based on serial measures

2017 EvidenceUpdates

3. 4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate. (PubMed)

4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate. Our objective was to estimate 4-year healthcare costs associated with the metabolic profile of patients before and after 1 year of treatment with phentermine (15 mg) and topiramate extended-release (92 mg) [phentermine-topiramate ER].Using a medical records database, we created two patient cohorts reflecting metabolic profiles of subjects before (...) and after phentermine-topiramate ER therapy during the 1-year CONQUER trial. We matched database patients with trial subjects by age, sex, body mass index (BMI), and hypertension, glycemic, and triglyceride status. We collected real-world data on emergency department and outpatient visits, hospitalizations, and drug prescriptions over 4 years, linking them to reimbursements to estimate US private insurance costs for post-trial (n = 2295) versus pre-trial intention-to-treat (ITT) patients (n = 2295

Full Text available with Trip Pro

2015 Drugs - real world outcomes

4. Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination

Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination Prescrire IN ENGLISH - Spotlight: Archive ''Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination'', 1 March 2013 {1} {1} {1} | | > > > Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :   (...) |   |  Spotlight Archives Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination FEATURED REVIEW Overweight and obese patients must not be exposed to the topiramate + phentermine combination. No beneficial impact on clinical complications of obesity has been demonstrated. A portion of the weight lost is regained after treatment withdrawal. And numerous serious adverse effects have already been observed. Full review (4 pages) available

2014 Prescrire

5. Qsiva - phentermine / topiramate

Qsiva - phentermine / topiramate 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 21 February 2013 EMA/CHMP/108692/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Qsiva International non-proprietary name (...) : PHENTERMINE / TOPIRAMATE Procedure No. EMEA/H/C/002350/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Qsiva CHMP assessment report EMA/CHMP/108692/2013 Page 2/91 Table of contents 1. Background information on the procedure 5 1.1. Submission of the dossier 5 1.2. Manufacturers 6 1.3. Steps taken for the assessment of the product 6 2. Scientific discussion 7 2.1. Introduction 7 2.2. Quality aspects 9 2.2.1. Introduction 9 2.2.2. Active

2013 European Medicines Agency - EPARs

6. Qsymia (phentermine and topiramate extended-release)

Qsymia (phentermine and topiramate extended-release) Drug Approval Package: Qsymia (phentermine and topiramate extended-release) NDA #22580Orig1s000 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Qsymia (phentermine and topiramate extended-release) Capsules CIV Company: Vivus, Inc. Application No.: 22580Orig1s000 Approval Date: 07/17/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF

2012 FDA - Drug Approval Package

7. Suprenza (phentermine hydrochloride) orally dissolving tablets

Suprenza (phentermine hydrochloride) orally dissolving tablets Drug Approval Package: Suprenza (phentermine hydrochloride) NDA #202088 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Suprenza (phentermine hydrochloride) orally dissolving tablets (ODT), 15 mg, 30 mg, and 37.5 mg Company: Citius Pharmaceuticals, LLC Application No.: 202088 Approval Date: 03/27/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796

2012 FDA - Drug Approval Package

8. Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors

Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors | BMJ Evidence-Based Medicine We (...) of institutional accounts Username * Password * your user name or password? You are here The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors Article Text Therapeutics Randomised controlled trial The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity

2012 Evidence-Based Medicine (Requires free registration)

9. Suprenza (phentermine hydrochloride) orally dissolving tablets

Suprenza (phentermine hydrochloride) orally dissolving tablets Drug Approval Package: Suprenza (phentermine hydrochloride) NDA #202088 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Suprenza (phentermine hydrochloride) orally dissolving tablets, 15 mg and 30 mg Company: Citius Pharmaceuticals, LLC Application No.: 202088 Approval Date: 06/13/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2011 FDA - Drug Approval Package

10. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. (PubMed)

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. We therefore assessed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct to diet (...) and lifestyle modification for weight loss and metabolic risk reduction in individuals who were overweight and obese, with two or more risk factors.In this 56-week phase 3 trial, we randomly assigned overweight or obese adults (aged 18-70 years), with a body-mass index of 27-45 kg/m(2) and two or more comorbidities (hypertension, dyslipidaemia, diabetes or prediabetes, or abdominal obesity) to placebo, once-daily phentermine 7·5 mg plus topiramate 46·0 mg, or once-daily phentermine 15·0 mg plus topiramate

2011 Lancet